The Potential of Molecular Vaccines in the Prevention of Breast Cancer
DOI:
https://doi.org/10.54097/qbd7te75Keywords:
Breast Cancer, Molecular Vaccines, Genetic Vaccine, Peptide VaccineAbstract
Breast cancer is the most common malignant tumour among women worldwide and poses a serious threat to public health; the development of highly effective and safe preventive measures is key to reducing its disease burden. As a highly promising immunopreventive strategy, the potential of molecular vaccines in breast cancer prevention has attracted considerable attention. This paper adopts an 'Immunological Basis -- Platform Technology -- Prevention Strategy' framework to systematically reviews the immunological theoretical basis of molecular vaccines in breast cancer prevention, the technical characteristics and preclinical evidence of the three mainstream vaccine platforms (nucleic acid vaccines, peptide vaccines and cell-based vaccines), as well as the latest advances in immunological intervention strategies for ductal carcinoma in situ (DCIS). It comprehensively explores the feasibility of applying molecular vaccines to breast cancer prevention, providing theoretical references and insights for subsequent related research and clinical translation.
Downloads
References
[1] Sauter, E. R. (2018). Breast cancer prevention: Current approaches and future directions. European Journal of Breast Health, 14(2), 64. https://doi.org/10.5152/ejbh.2018.3978. DOI: https://doi.org/10.5152/ejbh.2018.3978
[2] Zachariah, N. N., Basu, A., Gautam, N., Ramamoorthi, G., Kodumudi, K. N., Kumar, N. B., Loftus, L., & Czerniecki, B. J. (2021). Intercepting premalignant, preinvasive breast lesions through vaccination. Frontiers in Immunology, 12, 786286. https://doi.org/10.3389/fimmu.2021.786286. DOI: https://doi.org/10.3389/fimmu.2021.786286
[3] Pallerla, S., Abdul, A. R. M., Comeau, J., & Jois, S. (2021). Cancer vaccines, treatment of the future: With emphasis on HER2 positive breast cancer. International Journal of Molecular Sciences, 22(2), 779. https://doi.org/10.3390/ijms22020779. DOI: https://doi.org/10.3390/ijms22020779
[4] Palladini, A., Landuzzi, L., Lollini, P. L., & Nanni, P. (2018). Cancer immunoprevention: From mice to early clinical trials. BMC Immunology, 19(1), 42. https://doi.org/10.1186/s12865 018 0253 0. DOI: https://doi.org/10.1186/s12865-018-0253-0
[5] Agahozo, M. C., Hammerl, D., Debets, R., Kok, M., & van Deurzen, C. H. M. (2018). Tumor infiltrating lymphocytes and ductal carcinoma in situ of the breast: Friends or foes? Modern Pathology, 31(8), 1234 1243. https://doi.org/10.1038/s41379 018 0030 x. DOI: https://doi.org/10.1038/s41379-018-0030-x
[6] Stergiou, N., Gaidzik, N., Heimes, A. S., Dietzen, S., Besenius, P., Jäkel, J., Brenner, W., Schmidt, M., Kunz, H., & Schmitt, E. (2018). Reduced breast tumor growth after immunization with a tumor restricted MUC1 glycopeptide conjugated to tetanus toxoid. Cancer Immunology Research, 6(11), 1342 1352. https://doi.org/10.1158/2326 6066.cir 18 0256.
[7] Tuohy, V. K., & Johnson, J. M. (2020). Primary immunoprevention of adult onset cancers by vaccinating against retired tissue specific self proteins. Seminars in Immunology, 50, 101392. https://doi.org/10.1016/j.smim.2020.101392. DOI: https://doi.org/10.1016/j.smim.2020.101392
[8] Edechi, C. A., Ikeogu, N., Uzonna, J. E., & Myal, Y. (2019). Regulation of immunity in breast cancer. Cancers, 11(8), 1080. https://doi.org/10.3390/cancers11081080. DOI: https://doi.org/10.3390/cancers11081080
[9] Cruz Reyes, N., & Radisky, D. C. (2023). Inflammation, infiltration, and evasion—Tumor promotion in the aging breast. Cancers, 15(6), 1836. https://doi.org/10.3390/cancers15061836. DOI: https://doi.org/10.3390/cancers15061836
[10] Lopes, A., Vandermeulen, G., & Préat, V. (2019). Cancer DNA vaccines: Current preclinical and clinical developments and future perspectives. Journal of Experimental & Clinical Cancer Research, 38(1), 146. https://doi.org/10.1186/s13046 019 1154 7. DOI: https://doi.org/10.1186/s13046-019-1154-7
[11] Jiang, X., & Liu, Q. (2023). mRNA vaccination in breast cancer: Current progress and future direction. Journal of Cancer Research and Clinical Oncology, 149(12), 5229 5244. https://doi.org/10.1007/s00432 023 04805 z.
[12] Ghasemi Dehkordi, P., Doosti, A., & Jami, M. S. (2019). The concurrent effects of azurin and Mammaglobin A genes in inhibition of breast cancer progression and immune system stimulation in cancerous BALB/c mice. 3 Biotech, 9(5), 180. https://doi.org/10.1007/s13205 019 1804 7. DOI: https://doi.org/10.1007/s13205-019-1804-7
[13] Eskandari, A., Leow, T. C., Rahman, M. B. A., & Oslan, S. N. (2024). Advances in therapeutic cancer vaccines, their obstacles, and prospects toward tumor immunotherapy. Molecular Biotechnology, 66(8), 1929 1946. https://doi.org/10.1007/s12033 024 01144 3.
[14] Tomasicchio, M., Semple, L., Esmail, A., Meldau, R., Randall, P., Pooran, A., Davids, M., Cairncross, L., Anderson, D., Downs, J., Malherbe, F., Novitzky, N., Panieri, E., Oelofse, S., Londt, R., Naiker, T., & Dheda, K. (2018). An autologous dendritic cell vaccine polarizes a Th 1 response which is tumoricidal to patient derived breast cancer cells. Cancer Immunology, Immunotherapy, 67(11), 1715 1728. https://doi.org/10.1007/s00262 018 2238 5.
[15] Qian, D., Li, J., Huang, M., Cui, Q., Liu, X., & Sun, K. (2023). Dendritic cell vaccines in breast cancer: Immune modulation and immunotherapy. Biomedicine & Pharmacotherapy, 163, 114685. https://doi.org/10.1016/j.biopha.2023.114685. DOI: https://doi.org/10.1016/j.biopha.2023.114685
[16] Gautam, N., Ramamoorthi, G., Champion, N., Han, H. S., & Czerniecki, B. J. (2023). Reviewing the significance of dendritic cell vaccines in interrupting breast cancer development. Molecular Aspects of Medicine, 92, 101239. https://doi.org/10.1016/j.mam.2023.101239. DOI: https://doi.org/10.1016/j.mam.2023.101239
[17] Zhang, L., Zhou, X., Sha, H., Xie, L., & Liu, B. (2022). Recent progress on therapeutic vaccines for breast cancer. Frontiers in Oncology, 12, 905832. https://doi.org/10.3389/fonc.2022.905832. DOI: https://doi.org/10.3389/fonc.2022.905832
[18] Wilkes, J. G., Czerniecki, B. J., & Costa, R. L. B. (2020). Treatment from within: Ductal carcinoma as an opportunity to harness the immune system. Current Breast Cancer Reports, 12(4), 225 233. https://doi.org/10.1007/s12609 020 00356 1.
[19] Stanton, S. E., Schlumbohm, J., & Disis, M. L. (2022). Abstract PR007: Candidate antigens for a ductal carcinoma in situ vaccine, essential for breast cancer cell survival across multiple subtypes, are immunogenic in DCIS and IBC. Cancer Prevention Research, 15(Suppl 1), PR007. https://doi.org/10.1158/1940 6215.dcis22 pr007. DOI: https://doi.org/10.1158/1940-6215.DCIS22-PR007
[20] Buchheit, J. T., Schacht, D., & Kulkarni, S. (2023). Update on management of ductal carcinoma in situ. Clinical Breast Cancer, 24(2), 148 156. https://doi.org/10.1016/j.clbc.2023.12.010. DOI: https://doi.org/10.1016/j.clbc.2023.12.010
[21] Liu, T., Yu, J., Gao, Y., Ma, X., Jiang, S., Gu, Y., & Ming, W. (2023). Prophylactic interventions for hereditary breast and ovarian cancer risks and mortality in BRCA1/2 carriers. Cancers, 16(1), 103. https://doi.org/10.3390/cancers16010103. DOI: https://doi.org/10.3390/cancers16010103
[22] Mansour, R., Abunasser, M., Sharaf, B., & Abdel Razeq, H. (2025). Update in the clinical utilization of chemoprevention for breast cancer: A narrative review. Frontiers in Oncology, 15, 1435253. https://doi.org/10.3389/fonc.2025.1435253. DOI: https://doi.org/10.3389/fonc.2025.1435253
[23] Jakub, J. W., Peled, A. W., Gray, R. J., Greenup, R. A., Kiluk, J. V., Sacchini, V., McLaughlin, S. A., Tchou, J. C., Vierkant, R. A., Degnim, A. C., & Willey, S. (2018). Oncologic safety of prophylactic nipple sparing mastectomy in a population with BRCA mutations. JAMA Surgery, 153(2), 140 147. https://doi.org/10.1001/jamasurg.2017.3422. DOI: https://doi.org/10.1001/jamasurg.2017.3422
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
